133 related articles for article (PubMed ID: 37907382)
21. Utility of mutational analysis for risk stratification of indeterminate thyroid nodules in a real-world setting.
Torrecillas V; Sharma A; Neuberger K; Abraham D
Clin Endocrinol (Oxf); 2022 Apr; 96(4):637-645. PubMed ID: 34605038
[TBL] [Abstract][Full Text] [Related]
22. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
Gortakowski M; Feghali K; Osakwe I
Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
[No Abstract] [Full Text] [Related]
23. Heterogeneity in Positive Predictive Value of RAS Mutations in Cytologically Indeterminate Thyroid Nodules.
Nabhan F; Porter K; Lupo MA; Randolph GW; Patel KN; Kloos RT
Thyroid; 2018 Jun; 28(6):729-738. PubMed ID: 29665745
[TBL] [Abstract][Full Text] [Related]
24. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
25. Cytological features and nuclear scores: Diagnostic tools in preoperative fine needle aspiration of indeterminate thyroid nodules with RAS or BRAF K601E mutations?
Ravella L; Lopez J; Descotes F; Giai J; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Decaussin-Petrucci M
Cytopathology; 2021 Jan; 32(1):37-44. PubMed ID: 32803788
[TBL] [Abstract][Full Text] [Related]
26. A five-gene panel refines differential diagnosis of thyroid nodules.
Lu SY; Chen YC; Zhu CF; Chen J; Zhou QY; Zhang MM; Zhang QY; Lu M; Yang L; Wu J; Zhao SX; Song HD; Ye XP
J Clin Lab Anal; 2021 Sep; 35(9):e23920. PubMed ID: 34318534
[TBL] [Abstract][Full Text] [Related]
27. Clinical Factors Influencing the Performance of Gene Expression Classifier Testing in Indeterminate Thyroid Nodules.
Wu JX; Young S; Hung ML; Li N; Yang SE; Cheung DS; Yeh MW; Livhits MJ
Thyroid; 2016 Jul; 26(7):916-22. PubMed ID: 27161519
[TBL] [Abstract][Full Text] [Related]
28. Preoperative detection of malignancy in fine-needle aspiration cytology (FNAC) smears with indeterminate cytology (Bethesda III, IV) by a combined molecular classifier.
Titov S; Demenkov PS; Lukyanov SA; Sergiyko SV; Katanyan GA; Veryaskina YA; Ivanov MK
J Clin Pathol; 2020 Nov; 73(11):722-727. PubMed ID: 32213552
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules: A Randomized Clinical Trial.
Livhits MJ; Zhu CY; Kuo EJ; Nguyen DT; Kim J; Tseng CH; Leung AM; Rao J; Levin M; Douek ML; Beckett KR; Cheung DS; Gofnung YA; Smooke-Praw S; Yeh MW
JAMA Oncol; 2021 Jan; 7(1):70-77. PubMed ID: 33300952
[TBL] [Abstract][Full Text] [Related]
30. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.
Silaghi CA; Lozovanu V; Georgescu CE; Georgescu RD; Susman S; Năsui BA; Dobrean A; Silaghi H
Front Endocrinol (Lausanne); 2021; 12():649522. PubMed ID: 34054725
[TBL] [Abstract][Full Text] [Related]
31. Real-world Comparison of Afirma GEC and GSC for the Assessment of Cytologically Indeterminate Thyroid Nodules.
San Martin VT; Lawrence L; Bena J; Madhun NZ; Berber E; Elsheikh TM; Nasr CE
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31665322
[TBL] [Abstract][Full Text] [Related]
32. Update on Molecular Testing for Cytologically Indeterminate Thyroid Nodules.
Bose S; Sacks W; Walts AE
Adv Anat Pathol; 2019 Mar; 26(2):114-123. PubMed ID: 30664001
[TBL] [Abstract][Full Text] [Related]
33. McGill Thyroid Nodule Score in Differentiating Benign and Malignant Pediatric Thyroid Nodules: A Pilot Study.
Canfarotta M; Moote D; Finck C; Riba-Wolman R; Thaker S; Lerer TJ; Payne RJ; Cote V
Otolaryngol Head Neck Surg; 2017 Oct; 157(4):589-595. PubMed ID: 28653562
[TBL] [Abstract][Full Text] [Related]
34. EIF1AX mutation in thyroid tumors: a retrospective analysis of cytology, histopathology and co-mutation profiles.
Elsherbini N; Kim DH; Payne RJ; Hudson T; Forest VI; Hier MP; Payne AE; Pusztaszeri MP
J Otolaryngol Head Neck Surg; 2022 Nov; 51(1):43. PubMed ID: 36371345
[TBL] [Abstract][Full Text] [Related]
35. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
Jug RC; Datto MB; Jiang XS
Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
[TBL] [Abstract][Full Text] [Related]
36. The first Canadian experience with the Afirma® gene expression classifier test.
Kay-Rivest E; Tibbo J; Bouhabel S; Tamilia M; Leboeuf R; Forest VI; Hier MP; Savoury L; Payne RJ
J Otolaryngol Head Neck Surg; 2017 Apr; 46(1):25. PubMed ID: 28372589
[TBL] [Abstract][Full Text] [Related]
37. Does the likelihood of malignancy in thyroid nodules with RAS mutations increase in direct proportion with the allele frequency percentage?
Hudson TJ; Pusztaszeri MP; Hier MP; Forest VI; Yang JW; Payne RJ
J Otolaryngol Head Neck Surg; 2023 Feb; 52(1):12. PubMed ID: 36774522
[TBL] [Abstract][Full Text] [Related]
38. Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules.
Brauner E; Holmes BJ; Krane JF; Nishino M; Zurakowski D; Hennessey JV; Faquin WC; Parangi S
Thyroid; 2015 Jul; 25(7):789-96. PubMed ID: 25962906
[TBL] [Abstract][Full Text] [Related]
39.
Sfreddo HJ; Koh ES; Zhao K; Swartzwelder CE; Untch BR; Marti JL; Roman BR; Dublin J; Wang RS; Xia R; Cohen JM; Xu B; Ghossein R; Givi B; Boyle JO; Tuttle RM; Fagin JA; Wong RJ; Morris LGT
Thyroid; 2024 Apr; 34(4):450-459. PubMed ID: 38407967
[No Abstract] [Full Text] [Related]
40. PREDICTIVE VALUE OF SOMATIC MUTATIONS FOR THE DEVELOPMENT OF MALIGNANCY IN THYROID NODULES BY CYTOPATHOLOGY.
Halászlaki C; Tóbiás B; Balla B; Kósa JP; Horányi J; Bölöny E; Nagy Z; Speer G; Járay B; Székely E; Istók R; Székely T; Putz Z; Dank M; Lakatos P; Takács I
Endocr Pract; 2016 Sep; 22(9):1081-7. PubMed ID: 27214302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]